

**Table 1:** Sales forecasts of selected, approved oligonucleotide-based drugs.

Product	Company	Modality	Indication	Peak Sales (USD)
Amvuttra	Alnylam	siRNA	ATTR amyloidosis	~7–9 bn (2029) <sup>i</sup>
Leqvio	Novartis	siRNA	Hypercholesterolemia	4+ bn (2030) <sup>ii</sup>
CASGEVY	Vertex Pharmaceuticals	Gene editing (CRISPR/Cas9)	Sickle cell disease, beta-thalassemia	3.9 bn (>2030) <sup>iii</sup>
Wainua	IONIS / AstraZeneca	ASO	hATTR polyneuropathy	3.5–7.0 bn(2029) <sup>iv</sup>
Tryngolza	IONIS	ASO	Familial chylomicronemia syndrome (FCS)	2.5 bn (2030) <sup>v</sup>
Rytelo	Geron Netherlands	ASO	Myelodysplastic syndrome (MDS)	1.5–2.0 bn (~2029) <sup>vi</sup>
Izervay	Astellas	Aptamer	Geographic atrophy (AMD)	1.3–2.6 bn(~2029) <sup>vii</sup>
Redempro	Arrowhead Pharmaceuticals	siRNA	Familial chylomicronemia syndrome (FCS)	1.8 bn (2036) <sup>viii</sup>
Qfitlia	Sanofi	siRNA	Hemophilia A/B	~1.3 bn (2030) <sup>ix</sup>
Oxlumo	Alnylam	siRNA	Primary hyperoxaluria type 1	241 m (2026) <sup>x</sup> 0.4–0.6 bn(2032) <sup>xi</sup>
Dawnzera	IONIS	ASO	Hereditary angioedema (HAE)	0.567 bn (2035) <sup>xii</sup>

<sup>i</sup> <https://www.biopharmadive.com/news/alnylam-amvuttra-q2-2025-sales-ttr-cardiomyopathy-guidance/756477/>

<sup>ii</sup> <https://www.investing.com/news/transcripts/earnings-call-transcript-novartis-q4-2025-earnings-beat-forecasts-stock-jumps-93CH-4485228>

<sup>iii</sup> <https://www.statnews.com/2023/11/16/crispr-vertex-sickle-cell-beta-thalassemia-casgev-y-approval/>

<sup>iv</sup> <https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-ionis-astrazenecas-nerve-disease-drug-2023-12-21/>

<sup>v</sup> <https://www.fiercepharma.com/pharma/jpm26-ionis-bolstered-strong-launch-tryngolza-doubles-its-sales-projection-new-indication-2b>

<sup>vi</sup> <https://firstwordpharma.com/story/5941457>

<sup>vii</sup> <https://firstwordpharma.com/story/5934840>

<sup>viii</sup> <https://www.spglobal.com/market-intelligence/en/news-insights/research/2025/11/redempro-approval-mark-arrowheads-entry-into-fcs-shtg-to-deliver-larger-growth>

<sup>ix</sup> <https://www.biospace.com/fda/sanofi-alnylam-win-first-rnai-approval-for-hemophilia-a-and-b>

<sup>x</sup> <https://insights.citeline.com/in-vivo/2026s-sales-growth-winners-and-losers-4307XRQMURHRVGN4FUYE5ORI/>

<sup>xi</sup> <https://www.fiercepharma.com/pharma/alnylam-nets-third-fda-nod-plans-unique-value-based-deals>

<sup>xii</sup> <https://www.spglobal.com/market-intelligence/en/news-insights/research/2025/10/ionis-dawnzera-set-for-steady-growth-as-hae-rivals-kalvista-and-csl-pull-ahead>